Citations

Mayo Clinic

Showing 10 of 108585 citations.

Dual-Path Model With Fresnel Zone-Based Voting For Human Activity Recognition Using WI-FI
Djogo, Radomir , Salehinejad, Hojjat , Hasanzadeh, Navid , Valaee, Shahrokh

2023 IEEE 33rd International Workshop on Machine Learning for Signal Processing (MLSP) | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/mlsp55844.2023.10285927 Get It

P022 Sleep Biomarker Phenotyping of Neurodegenerative Disorders Using Artificial Intelligence – A Pilot Study
Levendowski, Daniel J. , Walsh, Christine M. , Lee‐Iannotti, Joyce , Mazeika, Gandis, Tsuang, Debby W. , Neylan, Thomas C. , Berka, Chris , Boeve, Bradley F. , Louis, Erik K. St.

Sleep Advances | October 23, 2023 | Volume: 4 | Issue: Supplement_1 | Pages: A42-A42

10.1093/sleepadvances/zpad035.107 Get It

Abstract Introduction In this pilot study, we explored sleep biomarker risk probabilities for different neurodegenerative disorder (NDD) phenotypes across a spectrum of NDD patients, compared with controls. Methods We analyzed a cohort of patients with different NDD phenotypes who underwent in-home recordings with Sleep Profiler, including Lewy body disease (LBD=20), Alzheimer’s disease dementia (AD=29), and isolated REM sleep behavior disorder (iRBD=19). Controls with an MMSE>28 (CG=61) and patients with Parkinson disease (PD=16) and mild-cognitive-impairment (MCI=41) also participated. We developed a machine-learning classifier that assigned NDD probabilities for LBD, AD, iRBD, and CG. The input variables included: time-REM, non-REM hypertonia, autonomic-activation index, spindle-duration, atypical-N3, time-supine, sleep-efficiency, relative-theta, and theta/alpha. Probabilities >50% were assigned “likely”, and for CG>=50% and a NDD group probability 20-50%, the assignment was normal “plus”. Probability assignments were then made for the NDD and CG groups, then further applied to the PD and MCI patient groups. Results The CG group participants were assigned Normal-Likely=74%, Normal+AD=11%, Normal+iRBD=5%, iRBD-Likely=5%, and AD-Likely=5%. LBD patient distributions were LBD-Likely=70%, iRBD-Likely=5%, AD-Likely=5%, Normal+LBD=5%, Normal+iRBD=5%, Normal+AD=5%, and Normal-Likely=5%. AD group distributions were AD-Likely=71%, LBD-Likely=4%, Normal+AD=14%, Normal+iRBD=4%, Normal-Likely=7%. iRBD patients were characterized with iRBD-Likely=37%, LBD-Likely=5%, AD-Likely=5%, Normal+iRBD=27%, Normal-Likely=26%. PD patients were assigned iRBD-Likely=29%, LBD-likely=14%, AD-Likely=14%, Normal+iRBD=21%, Normal+AD=7%, Normal-Likely=14%. MCI distributions were AD-Likely=45%, LBD-Likely=8%, iRBD-Likely=5%, Normal+AD=21%, Normal-Likely=13%. Conclusions For LBD, AD and CG groups, correct risk assignments were >70% while gross misclassifications were <10%. Classification patterns for PD, MCI and iRBD were disbursed in a manner consistent with the range of severities expected in each group.
P025 Atypical N3 Sleep: A Biomarker for Altered Mental Status in Lewy Body Disease?
Levendowski, Daniel J. , Lee‐Iannotti, Joyce , Walsh, Christine M. , Mazeika, Gandis, Neylan, Thomas C. , Tsuang, Debby W. , Berka, Chris , Boeve, Bradley F. , Louis, Erik K. St.

Sleep Advances | October 23, 2023 | Volume: 4 | Issue: Supplement_1 | Pages: A43-A43

10.1093/sleepadvances/zpad035.110 Get It

Abstract Introduction Atypical N3 sleep (AN3=delta waves with limited theta and sigma) has been associated with ICU delirium and sepsis and averaged 25% of sleep time in Japanese ICU patients. We were interested in exploring whether AN3 might be a marker of cerebral dysfunction in ambulatory patients across a range of neurodegenerative disorders, including those with a dementia diagnosis. Methods After ethics review and with informed consent, patients with Lewy body disease (DLB/PDD: n=20,male=90%,age=70 + 6.2), Alzheimers disease dementia (AD: n=29,male=79%,age=75 + 6.7), Parkinson disease (PD: n=16,male=69%,age=67 + 8.7), mild cognitive impairment (MCI: n=41,male=63%,age=70 + 8.5), isolated REM sleep behavior disorder (iRBD: n=19,male=74%,age=64 + 9.6) and a control group (CG: n=61,male=47%,age=65 + 8.3) were studied with the Sleep Profiler and auto-detected AN3 computed. Between-group comparisons were assessed with Mann-Whitney U and Chi-square tests. Results The mean percentages of sleep time with AN3 were significantly greater in DLB/PDD (8 + 12.3) vs. PD (4 + 10.8), AD (2 + 3.7), MCI (2 + 2.3), iRBD (1 + 1.6), and CG (1 + 2.4)(all p<0.02). The proportions of records with abnormal AN3 (>5% of sleep time) were significantly greater in those with DLB/PDD=35% vs. MCI=10%, iRBD=5% and CG=5% (all p<0.05), but not AD=17% and PD=13%. Conclusions Further investigations are needed to determine if abnormal AN3 may be a biomarker that distinguishes patients with Lewy body spectrum diseases from alternative pathologies and/or could be helpful in monitoring the side effects of CNS-acting medications
O065 Autonomic Dysregulation During Sleep in Parkinsonian Spectrum Disorders
Levendowski, Daniel J. , Cho, Y , Walsh, Christine M. , Lee‐Iannotti, Joyce , Mazieka, G, Cho, Y, Tsuang, Debby W. , Berka, Chris , Boeve, Bradley F. , Neylan, Thomas C. , Louis, Erik K. St.

Sleep Advances | October 23, 2023 | Volume: 4 | Issue: Supplement_1 | Pages: A26-A26

10.1093/sleepadvances/zpad035.065 Get It

Abstract Introduction Symptoms associated with autonomic nervous system dysfunction are common to patients with neurodegenerative disorders (NDD) resulting from the accumulation of α-synuclein in the neurons and glial cells. In this study we investigate whether a novel biomarker, the autonomic activation index, can discriminate these potentially affected NDD groups. Methods After ethics review and with informed consent, patients with Lewy body disease (DLB/PDD: n=20%), Alzheimer’s disease dementia (AD: n=27), Parkinson disease (PD: n=14), mild cognitive impairment (MCI: n=37), isolated REM sleep behavior disorder (iRBD: n=15) and a control group (CG: n=58) were studied with the Sleep Profiler. AAI was based on a 6 BPM increase in pulse rate compared to the previous/subsequent 10th second. Between-group comparisons were assessed with Mann-Whitney U and Chi-square tests. Results The AAI values for the DLB/PDD patients were decreased compared to the AD, MCI (both p<0.03), and CG (p<0.0005), while the PD was less than AD and MCI (both < 0.05) and CG (p<0.002). The proportions of cases with abnormal AAI values (<10 events/h) was greatest in DLB/PDD patients, and greater than in ADem (p<0.02), MCI (p<0.02) and CG (p<0.0001), while AAI in PD and iRBD was greater than in CG (p<0.007 and 0.05 respectively). Conclusions These findings suggest that the AAI can be used to objectively confirm subjective complaints of autonomic dysfunction symptoms in patients with synucleinopathies. Longitudinal studies are needed determine factors that influence changes in the AAI.
P012 Head Position During Sleep: Potential Implications for Patients with Neurodegenerative Disorders
Levendowski, Daniel J. , Walsh, Christine M. , Lee‐Iannotti, Joyce , Mazeika, Gandis, Neylan, Thomas C. , Tsuang, Debby W. , Berka, Chris , Boeve, Bradley F. , Louis, Erik K. St.

Sleep Advances | October 23, 2023 | Volume: 4 | Issue: Supplement_1 | Pages: A38-A38

10.1093/sleepadvances/zpad035.097 Get It

Abstract Introduction In 2015, Lee et al. observed sleeping position influenced the efficiency of glymphatic clearance in rats. In 2018, Levendowski et al. reported supine sleep was independently associated with neurodegenerative disorders (NDD)(odds ratio=3.7). This update further evaluates the comparative frequency of the supine sleep position across a spectrum of cognitive impairment, including patients diagnosed with a Parkinsonian spectrum disorder (PSD), Alzheimer’s disease dementia (AD) and mild cognitive impairment (MCI), compared with a control group (CG) of patients without a known cognitive disorder. Methods After ethics review and with informed consent, a control group (CG: n=170), PSD (n=36), AD (n=29) and MCI group (n=41) were studied in-home with the Sleep Profiler; 89% across two-nights. Between-group comparisons were assessed with Mann-Whitney U and Chi-square tests. Results The hours of supine sleep were greater in PSD=3.0 + 1.9, AD=3.2 + 2.0 and MCI=3.0 + 2.0 vs. CG=1.9 + 1.8 (all p<0.002). The proportion of patients with >2 hours of supine sleep were PSD=69%, AD=69% and MCI=59% vs. CG=39%, with odds ratios of PSD=3.6, AD=3.5 and MCI=2.2 (all p<0.001). Conclusions Here we provide further evidence for a relatively strong association between supine sleep and neurodegenerative disease including PSD, AD and MCI cohorts. The nature of this association remains unclear from cross sectional study designs. Future prospective studies should test if there is a causal link between supine sleep and subsequent development of neurodegeneration.
Spondyloptosis in Loeys‐Dietz syndrome
Lynch, Mary E. , Brandenburg, Joline E. , Pepperday, Cody A., White, Melanie J, White, Melanie J.

PM&R | October 23, 2023 | Volume: 16 | Issue: 6 | Pages: 644-646

10.1002/pmrj.13090 | PMID 37870406 Get It

Late Development of Pneumatoceles in Necrotizing Pneumonia
Kocer, Sila Y. , NC, Hull, Potter, D. Dean , Madigan, Theresa , Boland-Froemming, Jennifer, Demirel, Nadir , Hull, Nathan C.

No container title available | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.169808224.43398057/v1 Get It

Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ
Mi, Xinlei , Xu, Yanfei , Blanco, Luis Z. , Akasha, Azza M., Pilewskie, Melissa , Al‐Hilli, Zahraa , Hwang, E. Shelley , Guenther, Joseph M., Kocherginsky, Masha , Zhang, Shanshan , Helland, Thomas , Hustad, Simon Steinar, Gursel, Demirkan, Perloff, Marjorie , Lee, Oukseub , Khan, Seema A. , Degnim, Amy C. , Amin, Amanda Leigh , Benante, Kelly A. , Mellgren, Gunnar , Dimond, Eileen P. , Perloff, Marjorie, Heckman‐Stoddard, Brandy M.

JAMA Surgery | October 23, 2023 | Volume: 158 | Issue: 12 | Pages: 1265

10.1001/jamasurg.2023.5113 | PMID 37870954 Get It

Importance Oral tamoxifen citrate benefits women with ductal carcinoma in situ (DCIS), but concern about toxic effects has limited acceptance. Previous pilot studies have suggested transdermal 4-hydroxytamoxifen gel has equivalent antiproliferative efficacy to oral tamoxifen, with low systemic exposure. Objective To demonstrate that 4-hydroxytamoxifen gel applied to the breast skin is noninferior to oral tamoxifen in its antiproliferative effect in DCIS lesions. Design, Setting, and Participants This randomized, double-blind, phase 2 preoperative window trial was performed at multicenter breast surgery referral practices from May 31, 2017, to January 27, 2021. Among 408 women with estrogen receptor–positive DCIS who were approached, 120 consented and 100 initiated study treatment. The most common reasons for nonparticipation were surgical delay, disinterest in research, and concerns about toxic effects. Data were analyzed from January 26, 2021, to October 5, 2022. Intervention Random assignment to oral tamoxifen citrate, 20 mg/d, and gel placebo or 4-hydroxytamoxifen gel, 2 mg/d per breast, and oral placebo, for 4 to 10 weeks, followed by DCIS resection. Main Outcomes and Measures The primary end point was absolute change in DCIS Ki-67 labeling index (Ki67-LI). Secondary end points included 12-gene DCIS Score, breast tissue tamoxifen metabolite concentrations, tamoxifen-responsive plasma protein levels, and patient-reported symptoms. Noninferiority of Ki67-LI reduction by 4-hydroxytamoxifen gel was tested using analysis of covariance; within- and between-arm comparisons were performed with paired t tests for mean values or the Wilcoxon rank sum test for medians. Results Of 90 participants completing treatment (mean [SD] age, 55 [11] years; 8 [8.9%] Asian, 16 [17.8%] Black, 8 [8.9%] Latina, and 53 [58.9%] White), 15 lacked residual DCIS in the surgical sample, leaving 75 evaluable for the primary end point analysis (40 in the oral tamoxifen group and 35 in the 4-hydroxytamoxifen gel group). Posttreatment Ki67-LI was 3.3% higher (80% CI, 2.1%-4.6%) in the 4-hydroxytamoxifen gel group compared with the oral tamoxifen group, exceeding the noninferiority margin (2.6%). The DCIS Score decreased more with oral tamoxifen treatment (−16 [95% CI, −22 to −9.4]) than with 4-hydroxytamoxifen gel (−1.8 [95% CI, −5.8 to 2.3]). The median 4-hydroxytamoxifen concentrations deep in the breast were nonsignificantly higher in the oral tamoxifen group (5.7 [IQR, 4.0-7.9] vs 3.8 [IQR, 1.3-7.9] ng/g), whereas endoxifen was abundant in the oral tamoxifen group and minimal in the 4-hydroxytamoxifen gel group (median, 13.0 [IQR, 8.9-20.6] vs 0.3 [IQR, 0-0.3] ng/g; P < .001). Oral tamoxifen caused expected adverse changes in plasma protein levels and vasomotor symptoms, with minimal changes in the transdermal group. Conclusions and Relevance In this randomized clinical trial, antiproliferative noninferiority of 4-hydroxytamoxifen gel to oral tamoxifen was not confirmed, potentially owing to endoxifen exposure differences. New transdermal approaches must deliver higher drug quantities and/or include the most potent metabolites. Trial Registration ClinicalTrials.gov Identifier: NCT02993159
Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?
Espinoza‐Gutarra, Manuel , Ailawadhi, Sikander

Expert Review of Hematology | October 23, 2023 | Volume: 16 | Issue: 12 | Pages: 905-910

10.1080/17474086.2023.2273851 | PMID 37870168 Get It

Kidney Intrinsic Mechanisms as Novel Targets in Renovascular Hypertension
Eirin, Alfonso , Chade, Alejandro , Lerman, Lilach O. , Chade, Alejandro R , Eirin, Alfonso

Hypertension | October 23, 2023 | Volume: 81 | Issue: 2 | Pages: 206-217

10.1161/hypertensionaha.123.21362 | PMID 37869904 Get It

Almost a hundred years have passed since obstruction of the renal artery has been recognized to raise blood pressure. By now chronic renovascular disease (RVD) due to renal artery stenosis is recognized as a major source of renovascular hypertension and renal disease. In some patients, RVD unaccompanied by noteworthy renal dysfunction or blood pressure elevation may be incidentally identified during peripheral angiography. Nevertheless, in others, RVD might present as a progressive disease associated with diffuse atherosclerosis, leading to loss of renal function, renovascular hypertension, hemodynamic compromise, and a magnified risk for cardiovascular morbidity and mortality. Atherosclerotic RVD leads to renal atrophy, inflammation, and hypoxia but represents a potentially treatable cause of chronic renal failure because until severe fibrosis sets in the ischemic kidney, it retains a robust potential for vascular and tubular regeneration. This remarkable recovery capacity of the kidney begs for early diagnosis and treatment. However, accumulating evidence from both animal studies and randomized clinical trials has convincingly established the inadequate efficacy of renal artery revascularization to fully restore renal function or blood pressure control and has illuminated the potential of therapies targeted to the ischemic renal parenchyma to instigate renal regeneration. Some of the injurious mechanisms identified as potential therapeutic targets included oxidative stress, microvascular disease, inflammation, mitochondrial injury, and cellular senescence. This review recapitulates the intrinsic mechanisms that orchestrate renal damage and recovery in RVD and can be harnessed to introduce remedial opportunities.